Apellis Pharma
APLS41.0300.00% ( 0.000 )
Apellis Pharma (APLS)
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic c...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- 41.030
- Volume
- 0
- Turnover
- 0
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- 41.140
- Volume Ratio
- 0.00
- Turnover Ratio
- --
Apellis Pharma Analyst Rating
View MoreForecast & Rating
Apr 29, 2026Price forecast
$40.93-0.24%
Forecast & RatingHold
20analysts
- Strong buy5.00%
- Buy0.00%
- Hold95.00%
- Sell0.00%
- Strong sell0.00%
News
- Market Beat · Jul 29 at 06:26 AM
Biogen (NASDAQ:BIIB) Updates FY 2026 Earnings Guidance
- PUBT · Jul 29 at 05:00 AM
Biogen Q2 FY26 GAAP diluted EPS drops 85% to $0.66; revenue rises 3% to $2.74 billion
- benzinga_article · Jun 29 at 10:27 AM
Biogen: Key Takeaways From Needham’s Meeting With Top Management
- Pharmaceutical Technology · Jun 29 at 05:42 AM
Biogen trims Apellis pipeline and R&D team after $5.6bn takeover
- benzinga_article · Jun 18 at 10:07 AM
Biogen To Acquire RayThera For Up To $1 Billion, Expanding Immunology Pipeline
- StockTitan · Jun 17 at 09:59 AM
Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc. | BIIB Stock News
